Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.59 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.56 |
| ▸ | STAT3 | P40763 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838303 | 0.84 | MEN1 (0.66) | MEN1STAT3SMN1; SMN2LMNAHPGD | |
| SCHEMBL1921227 | 0.81 | LMNA (0.78) | MEN1STAT3SMN1; SMN2LMNAHPGD | |
| SCHEMBL12789847 | 0.79 | MEN1 (1.00) | MEN1ADRB2ADRB1ADRB3LIMK1 | |
| SCHEMBL4432115 | 0.76 | LMNA (0.72) | MEN1SMN1; SMN2LMNAHPGDKMT2A | |
| SCHEMBL4553748 | 0.73 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| SCHEMBL423214 | 0.72 | LIMK1 (0.72) | MEN1ADRB2ADRB1ADRB3LIMK1 | |
| SCHEMBL4433890 | 0.71 | ADRB2 (0.51) | MEN1ADRB2ADRB1ADRB3SMN1; SMN2 | |
| SCHEMBL1003329 | 0.71 | STK3 (0.81) | LIMK1MAPK1 | |
| SCHEMBL4765789 | 0.70 | LIMK1 (0.68) | MEN1ADRB2ADRB1ADRB3LIMK1 | |
| SCHEMBL6836530 | 0.70 | MEN1 (0.62) | MEN1LMNAKMT2AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207174-B2 | Beta-3 adrenergic receptor agonists; urinary tract infections, incontinence, gastrointestinal disorders, dysmenorrhea, obesity; tocolytic, anxiolytic, antidiabetic agents; antidepressants; 4-(2-hydroxy-3-(1-(5-phenylthieno[2,3-d]pyrimidin-4-yl)piperidin-4-ylamino)propoxy)phenol | 4SC AG (DE) | 2012-06-26 | — | — | US | disclosed |
| EP-2118086-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | SCHWARZ PHARMA AG (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008090140-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEREOF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | 4SC AG (DE) | 2008-07-31 | — | — | WO | disclosed |
| EP-1947103-A1 | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments | 4SC AG (DE) | 2008-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249114-A1 | ARYLOXYPROPANOLAMINES, METHODS OF PREPARATION THEROF AND USE OF ARYLOXYPROPANOLAMINES AS MEDICAMENTS | ADRB3, ADRB1, ADRB2 | MEN1 3925/4885ADRB2 3/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.